Table 1 Final product packaging and stability testing
Volume (mL) | viable cell concentration | Viable total nucleated cells | % TB viability | % Viable monocytes | |
|---|---|---|---|---|---|
Donor 1: 0-h | 250 | 3.30E+05 | 8.25E+07 | 97 | 81.2 |
2-h stability (RT) | 250 | 3.20E+05 | 8.00E+07 | 99 | NA |
4-h stability (RT) | 250 | 3.40E+05 | 8.50E+07 | 97 | 80.3 |
Donor 2: 0-h | 250 | 3.25E+05 | 8.13E+07 | 100 | 76.9 |
2-h stability (RT) | 250 | 3.40E+05 | 8.50E+07 | 98 | NA |
4-h stability (RT) | 250 | 3.05E+05 | 7.63E+07 | 97 | 64.9 |
Donor 3: 0-h | 250 | 4.68E+06 | 1.17E+09 | 98 | 66 |
2-h stability (RT) | 250 | 4.89E+06 | 1.22E+09 | 96 | NA |
4-h stability (RT) | 250 | 4.47E+06 | 1.12E+09 | 93 | 66.9 |
Donor 4: 0-h | 250 | 4.08E+06 | 1.02E+09 | 94 | 74.2 |
2-h stability (RT) | 250 | 3.53E+06 | 8.83E+08 | 96 | NA |
4-h stability (RT) | 250 | 3.31E+06 | 8.28E+08 | 95 | 73.7 |